Insulet's Q2 Omnipod revenues grew 23.8% at constant currency with expanding global adoption, particularly for its Omnipod 5 automated insulin delivery system. The company raised 2026 international guidance and is progressing on next-generation products including Omnipod 6. However, intense competition, macroeconomic pressures, and supply chain risks could limit future margin expansion and profitability.

Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Inc. and Hyliion Holdings Corp., alleging false statements and improper revenue recognition. Investors who purchased securities during specified periods are encouraged to join the class action before the October 5, 2026 deadline for lead plaintiff status. The firm is also handling a case against Insulet Corporation with an August 31 deadline.

Rosen Law Firm has filed class action lawsuits against Hyliion Holdings Corp. (HYLN) for alleged false statements regarding a business deal with a recently formed entity lacking actual operations, and potential insider trading by executives. A separate class action has been filed against Insulet Corporation (PODD) with an August 31, 2026 deadline for lead plaintiff motions. Both lawsuits allege material misstatements that caused investor losses.

Rosen Law Firm reminds investors of Insulet Corporation who purchased securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.

Rosen Law Firm reminds investors in Insulet Corporation (PODD) and Primoris Services Corporation (PRIM) of important class action lawsuit deadlines. Investors who purchased securities during specified periods and suffered losses exceeding $100,000 are encouraged to secure legal counsel before the August 31, 2026 deadline to potentially recover damages through contingency fee arrangements.

Rosen Law Firm is notifying investors in Primoris Services Corporation (PRIM) and Insulet Corporation (PODD) about ongoing securities class action lawsuits. Primoris investors who purchased stock between August 5, 2025 and June 22, 2026 can join the class action with a September 21, 2026 deadline for lead plaintiff status. The lawsuit alleges Primoris made false statements about cost estimation and project management for renewable energy projects, leading to material cost overruns. Insulet investors face an August 31, 2026 deadline.

Rosen Law Firm is encouraging investors who suffered losses exceeding $100,000 in Primoris Services Corporation (PRIM) and Insulet Corporation (PODD) to join securities class action lawsuits. The PRIM lawsuit alleges the company made false statements regarding cost estimation and project management for renewable energy projects, leading to significant cost overruns. The PODD lawsuit details are partially provided. Both cases have approaching deadlines for lead plaintiff applications.

A class action lawsuit has been filed against Insulet Corporation alleging that the company made materially false and misleading statements regarding its business operations and compliance policies. The complaint specifically claims that Insulet's manufacturing controls were defective, creating a foreseeable risk that products could violate safety regulations. Investors who purchased Insulet securities between May 21, 2025 and May 26, 2026 are encouraged to join the lawsuit, with a lead plaintiff deadline of August 31, 2026.

Rosen Law Firm is alerting Insulet Corporation investors who purchased securities between February 21, 2025 and May 26, 2026 about an August 31, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.

Pomerantz LLP filed a class action lawsuit against Insulet Corporation (PODD) for alleged securities fraud. The complaint alleges that Insulet made false statements about its manufacturing controls and failed to disclose defective procedures that created safety risks. Two voluntary medical device corrections were announced in March and May 2026, resulting in significant stock price declines of 6.88% and 5.07% respectively. Investors who purchased Insulet securities between February 21, 2025 and May 26, 2026 can join the class action.

The Portnoy Law Firm has filed a class action lawsuit on behalf of Insulet Corporation investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and failed to disclose the full scope of safety issues with its Omnipod insulin pump products. Two voluntary medical device corrections were announced in March and May 2026, resulting in stock price declines of 7% and 5% respectively. Investors have until August 31, 2026 to file a lead plaintiff motion.

Grabar Law Office has filed multiple shareholder investigations and securities fraud class action complaints against four major companies. ARS Pharmaceuticals faces allegations of misleading statements regarding CVS Caremark insurance coverage delays for its neffy product, resulting in a 24% stock decline. Hub Group is accused of material misstatements in financial statements from 2023-2025. Insulet Corporation faces claims over defective manufacturing controls leading to voluntary product corrections. Roblox is alleged to have misrepresented earnings growth projections and the impact of its age verification technology rollout.